key: cord-0919787-61pm699j authors: Alsenani, Faisal title: Potential Natural Candidates in the Treatment of Coronavirus date: 2021-06-10 journal: Saudi J Biol Sci DOI: 10.1016/j.sjbs.2021.06.008 sha: e6c25ff46d6fd87f829fe406bded4185269ccce8 doc_id: 919787 cord_uid: 61pm699j Many viral infections do not have treatments or resistant to existing antiviral therapeutic interventions, and a novel strategy is required to combat virus-mediated fatalities. A novel coronavirus (coronavirus disease 2019 [COVID-19]) emerged in Wuhan, China, in late 2019 and rapidly spread across the globe. COVID-19 has impacted human society with life-threatening and unprecedented health, social, and economic issues, and it continues to affect millions of people. More than 5,800 clinical trials are in place worldwide to develop treatments to eradicate COVID-19. Historically, traditional medicine or natural products, such as medicinal plants, marine organisms and microbes, have been efficacious in treating viral infections. Nevertheless, important parameters for natural products, including clinical trial information, pharmacokinetic data, potency and toxicity profiles, in vivo and in vitro data, and product safety require validation. In this review article, an evaluation is performed of the potential application of natural product-based antiviral compounds, including crude extracts and bioactive chemical compounds obtained from medicinal plants, marine organisms, and microbes, to treat the viral infections COVID-19. Coronaviruses, a large family of viruses that include severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), SARS-CoV-2, and Middle East respiratory syndrome coronavirus (MERS-CoV), have had a significant detrimental effect on the social, health, and economic components of human society since 2000. The manifestation of SARS-CoV-2 as coronavirus disease 2019 was initially transmitted to humans via bats and the latter has since become a global pandemic (1) . This paper covers the epidemiological data pertaining to the coronavirus family, the genetic profile of COVID-19, current viral therapeutic interventions practiced in hospitals, ongoing clinical trials, coronavirus drug development, and combination therapy. The use of naturally occurring chemical constituents in research in the treatment of COVID-19, for example, the use of natural antiviral compounds from marine sources and microbes, bioactive phytoconstituents (in the treatment of MERS-CoV), drug repurposing in antiviral therapy, and current antiviral interventions, are also discussed. For several decades, natural products, including plants, marine sources, and microbes, have been considered important components in the development of drugs used as various treatments. However, several natural resources are yet to be explored, along with therapeutic compounds derived from phytoconstituents, to alleviate hazardous and life-threatening pandemic diseases, such as COVID-19. Viruses are resistant to and unaffected by antiviral therapy owing to gene mutation. In terms of the drug discovery paradigm for SARS-CoV-2, the principal goal is to protect the human population against coronavirus with the help of potent compounds or interventions. Viruses can affect humans, animals, plants, insects, fungi, and bacteria. It has been well documented that only 15% of nearly 300,000 plant species have been processed for the systematic investigation of biologically potent active substances. In particular, compounds from marine and microbial resources have yet to be exploited as a treatment in pandemic disease. The term "virus" derives from Latin and means "poison" or "venom," and viruses are considered to be virulent in nature. Viruses were studied extensively by Louis Pasteur and other researchers at the end of the nineteenth century. Compared to bacteria, they were considered to be pathogens or tiny parasites (2) . Viruses have common characteristics; for example, they comprise a genome, DNA, or RNA central core enclosed by a protective protein shell. With viruses, the nucleic acid is double stranded in most cases; however, there are a few singlestranded DNA viruses (2) . The protective protein shell of viruses is enclosed within an envelope, referred to as a capsid, which holds proteins and lipids. The replication of the virus ensues once it enters the host's cells; without entry, reproduction cannot occur (2). The contagious viral particle inside the host's cell is known as a virion, and it is dependent upon the energy-producing protein "machinery" in the host's cell (2, 3) . Research studies performed on genome sequence analysis have revealed that SARS, SARS-CoV-2 (which causes COVID- 19) , and MERS-CoV belong to the genus Betacoronavirus (4) . Typically, the presentation of COVID-19 infection is mild when compared with other coronaviruses (4). With COVID-19, the genetic structure is identical to that of betacoronaviruses and comprises 14 open reading frames (ORFs) in total (i.e., 27 proteins). Of the ORFs, those numbered 1 and 2, found on the 5'terminal region of the gene, encode a total of 15 nonstructural proteins. The major proteins (envelope, membrane, nucleocapsid, and spike), together with eight accessory proteins, are encoded in the 3'-terminal regions (4) . Phylogenetic tree analysis was applied to SARS-CoV-2 to evaluate the genetic similarities and differences with other coronaviruses. The findings have shown that SARS-CoV-2 is more phylogenetically analogous to the bat SARS-like coronavirus, SARS-CoV; however, MERS-CoV and SARS-CoV share the same genetic family, with evidence of a distinctive viral evolution (i.e., SARS-CoV-2 versus MERS and SARS) (5) . Research work on the genomic link between SARS-CoV-2 and SARS family revealed that 380 th amino acid substitutions, mostly in non-structural protein genes (5) . Twenty-seven mutations were observed in genes that encode the viral spike protein that is chiefly responsible for viral entry and receptor binding (5) (6) (7) (8) (9) (10) . Coronaviruses belong to the family Coronaviridae that comprises positive-strand RNA and enveloped viruses with the capacity to severely infect mammals, birds, and other vertebrates (11) . Classification of the virus is based upon data obtained using sequence-based analysis (12, 13) . As per a contemporary classification developed by a Coronaviridae family study group, 39 species of coronavirus exist in 27 subgenera, two subfamilies, and five genera (14, 15) . In particular, coronaviruses belong to the order Nidovirales, suborder Cornidovirineae, and realm Riboviri (14) (15) (16) . COVID-19 is an infectious respiratory disease caused by a novel coronavirus, SARS-CoV-2, which first emerged in Wuhan, China, in late December 2019 (17) (18) (19) . The World Health Organization (WHO) declared COVID-19 to be a public health disaster of global concern on January 30, 2020, and a pandemic in March 2020. By May 30, 2021, the total number of confirmed cases and deaths globally were more than 169 million and 3. The SARS-CoV-2 virus particle is spherical, and the surface contains protruding projections (i.e. spike proteins). The virus uses these spikes to latch on to human cells. Subsequently, a structural change in the virus results in viral membrane fusion. Later, entry by the viral gene into the host cell takes place, which leads to the production of a large number of viruses. The spikes of SARS-CoV-2 bind to the human cell surface through the Angiotensinconverting enzyme 2 (ACE2) receptors (23) . The pattern of viral attachment and binding to the host cell was similarly identified during the SARS outbreak that occurred in 2002 (24) . Coronaviruses belong to a single-stranded positive-sense RNA enveloped virus family. They are roughly 60-140 nm in diameter, and the virion has a crown-like morphology and club-shaped glycoprotein projections (25, 26) . Regarding the pathophysiology of COVID-19, the first phase comprises viral load and host cell infection, which triggers an inflammatory response in the target cells. Excessive stimulation of the innate immune system causes critical inflammatory tissue destruction, leading to acute respiratory distress syndrome, multiple types of dysfunction, and septic shock in the later phase of viral infection. Of all the steps in viral infection, researchers have focused on the virus' life cycle. The symptoms of COVID-19 include a fever, cough, influenza-like symptoms, night sweats, muscle stiffness, dizziness, diarrhea, nausea, loss of appetite, chills, and pain (20). According to the World Health Organization and National Center for Immunization and Amide derivatives, two amino acid residues conjugated to the parent compound, along with free 30-COOH, had 70-fold greater antiviral effects against SARS-CoV compared to glycyrrhizin; nevertheless, cytotoxicity was increased, which meant a reduction in the SI (42) . Tanshinones, such as tanshinone I, tanshinone IIA, tanshinone IIB, dihydrotanshinone I, rosmariquinone, methyl tanshinonate, and cryptotanshinone, isolated from Salvia miltiorrhiza, inhibited SARS-CoV papain-like protease (PL pro ) and 3CL pro (43) . Excepting rosmariquinone, these compounds were noncompetitive enzyme isomerization inhibitors. Importantly, all tanshinone derivatives inhibited PL pro time dependently ( Figure 8) ; however, compounds pretreated with 3CL pro did not show enhanced inhibitory activity. Of the tanshinones, tanshinone I was found to be the most effective in inhibiting the deubiquitylation process (43) . (44) . Remarkable antiviral efficacy was attributed to mannose-binding lectins, while antiviral effects were also achieved by carbohydrate-binding lectins (i.e., glucose, galactose, galactose, Nacetylgalactosamine, and N-acetylaglucosamine). In this study, the natural lectins acted via two targets, the first of which appeared to be a viral attachment in the early phase of the replication cycle and the second of which was the final phase in the infectious cycle (44) . Houttuynia cordata, used as a component in a heat reduction and detoxification formulae, was also assessed for its anti-SARS-CoV efficacy. Research into the water extract of Houttuynia cordata revealed that the extract might trigger the significant and dose-dependent proliferation of mouse spleen lymphocytes. In addition, there was an increase in the levels of interleukin (IL)-2 and IL-10 and the CD4 + and CD8 + T cell count. In particular, the water extract contained anti-SARS-CoV 3CL pro and RNA-dependent RNA polymerase. An extract of Houttuynia cordata, administered orally at 16 g/kg to animals in an acute oral toxicity study, was not associated with toxic effects (46) . The extract of Rheum palmatum had a significant anti-SARS-CoV 3CL pro effect (IC 50 = 13.76 g/ml, a 96% inhibition rate) (47) . ORF-3a in SARS-CoV and human coronavirus OC43 (HCoV-OC43) codes the ion-permeable channel (the cation-selective channel, in particular) in infected cells, and this plays a key role in viral release. In another study, emodin blocked the release of the virus from infected cells and the 3a ion channel found in SARS-CoV and HCoV-OC43 (48) . Flavonol derivatives, kaempferol, acylated kaempferol glucoside, and kaempferol glycosides, were also evaluated for their ability to suppress viral release in the 3a channel (48) . Lin, Ho (52) (54) . The inhibition of entry by the virus into the target organism was achieved via binding by griffithsin with the spike proteins located in SARS-CoV (54) . Griffithsin has also been shown to be potent against coronaviruses in birds and mammals. In a study that evaluated SARS-CoV infection in a mouse model, it had a significant positive impact on morbidity and mortality (54) . In addition, the unwanted adverse effects of the immunological response by the host's cells to SARS-CoV pathogenesis were inhibited by griffithsin (54, 55) . Niclosamide has been prescribed as an anthelminthic drug for several years and was found to hinder the replication stage of SARS-CoV; it also effectively abolished the synthesis of viral antigens (at a concentration of 1.56 M) (56) . Docking approaches, such as homology modelling, involving a crystallographic structure that shows the binding pocket of the 3CL pro enzyme, were carried out to determine whether potent molecules would strongly bind with 3CL pro . Cinanserin, a serotonin antagonist, was isolated and underwent various bioassays, including a replicon system-based assay to evaluate HCoV-229E and a quantitative assay to assess infective SARS-CoV and HCoV-229E (57 (58) . Past results of past research on the antiviral potential of cepharanthine in relation to HCoV-OC43 and SARS-CoV was in agreement with the findings of this study (59) . The inhibiting potential of cepharanthine on viral entry and post entry processes was evaluated, and it was shown to have potent antiviral activity by preventing infection with coronavirus at these different stages (58) . The To summarize, traditional medicine has been an invaluable resource in the discovery of natural antiviral natural compounds for drug development, and it has numerous advantages, including abundant availability (i.e., of herbal and marine resources), minimal side-effects, robust resistance against viruses, cost-effectiveness, chemical diversity, and chemical novelty (65) (66) (67) (68) . In this review, several effective compounds are mentioned that have an inhibition effect against the coronavirus. Compounds that have the lowest inhibition concentration are considered the most effective, including luteolin, saikosaponin B2, silvestrol, griffithsin and cepharanthine. Natural products also have limitations such asperforming an assay of a natural product requires high-throughput screening and robust techniques as it is difficult to determine their mechanism of action and potential activity (69) . The chemical structures of bioactive substances are also complex in nature. In addition, the isolation, purification, characterization and accessibility of natural products is time consuming and expensive (70) . Lastly, legislation governing biological resources is perplexing (71, 72) . Many drug molecules present in the market have been inspired by natural products and traditional medicines. Therefore, hopefully, natural products will be found to provide a treatment solution to COVID-19. Global epidemiology of bat coronaviruses Medical Microbiology 4th edition: University of Texas Medical Branch at Galveston How do viruses cause different diseases? Emerging coronaviruses: genome structure, replication, and pathogenesis The 2019-new coronavirus epidemic: evidence for virus evolution Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes infections A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The lancet oncology Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell host and microbe The molecular biology of coronaviruses Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans Create ten new species a new genus in the subfamily Orthocoronavirinae of the family Coronaviridae five new species a new genus in the subfamily Serpentovirinae of the family Tobaniviridae. Proposal 2019021 S" Ac v1 Reorganization of the family Coronaviridae into two families, Coronaviridae (including the current subfamily Coronavirinae and the new subfamily Letovirinae) and the new family Tobaniviridae (accommodating the current subfamily Torovirinae and three other subfamilies), revision of the genus rank structure and introduction of a new subgenus rank Additional changes to taxonomy ratified in a special vote by the International Committee on Taxonomy of Viruses Archives of virology A novel coronavirus associated with severe acute respiratory syndrome Coronavirus as a possible cause of severe acute respiratory syndrome Identification of a novel coronavirus in patients with severe acute respiratory syndrome Covid-19: risk factors for severe disease and death Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. Cell host & microbe Global patterns in coronavirus diversity Medical Microbiology 4th edition: University of Texas Medical Branch at Galveston A review of coronavirus disease-2019 (COVID-19) Middle East respiratory syndrome coronavirus (MERS-CoV) -Saudi Arabia MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2 Clinical and Laboratory Findings of MERS-CoV infection The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Anticomplementary principles of a Chinese multiherb remedy for the treatment and prevention of SARS Antiviral effects of saikosaponins on human coronavirus 229E in vitro Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa Toona sinensis Roem tender leaf extract inhibits SARS coronavirus replication Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds Identification of natural compounds with antiviral activities against SARS-associated coronavirus Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction Immunomodulatory and anti-SARS activities of Houttuynia cordata Anti-SARS coronavirus 3C-like protease effects of Rheum palmatum L. extracts Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus Flavonoidmediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorbia neriifolia Bioactive pyranoxanthones from the roots of Calophyllum blancoi. Chemical and pharmaceutical bulletin Effective inhibition of MERS-CoV infection by resveratrol Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona-and picornaviruses Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirusrelated coronavirus model. Chinese medical journal Natural bisbenzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Complement activation and inflammation Complement in lung disease Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics IFNstimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses Medicinal and therapeutic potential of herbs and plant metabolites/extracts countering viral pathogens-current knowledge and future prospects Antiviral herbs-present and future Antiviral potentials of medicinal plants Antiviral potential of medicinal plants: an overview. International research journal of pharmacy Drug discovery and natural products: end of an era or an endless frontier? Strategies for discovering drugs from previously unexplored natural products Natural products as sources of new drugs from 1981 to The role of natural products in a modern drug discovery program The Authors declare no conflict of interest.